CYP2A13 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL249086	0.61	8/20
SCHEMBL520610	0.61	8/20
SCHEMBL428266	0.56	8/20
SCHEMBL110887	0.71	7/20
SCHEMBL111727	0.64	7/20
SCHEMBL249557	0.50	7/20
SCHEMBL428922	0.50	7/20
SCHEMBL296307	0.63	6/20
SCHEMBL260734	0.50	6/20
SCHEMBL465778	0.50	6/20
SCHEMBL159991	0.49	6/20
SCHEMBL260363	0.45	6/20
SCHEMBL110824	0.58	5/20
SCHEMBL230275	0.57	5/20
SCHEMBL304670	0.57	5/20
SCHEMBL249415	0.54	5/20
SCHEMBL465823	0.47	5/20
SCHEMBL62595	0.45	5/20
SCHEMBL60705	0.50	4/20
SCHEMBL578293	0.46	4/20

Clinical trials — most relevant to CYP2A13 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
OPTImization of the Dose of tacroliMUS by Bayesian Prediction	PHASE4	COMPLETED
Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication	PHASE4	COMPLETED
Study of Efficacy of CDZ173 in Patients With APDS/PASLI	PHASE2/PHASE3	COMPLETED
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL	PHASE1/PHASE2	UNKNOWN
Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis	PHASE2	RECRUITING
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer	PHASE2	RECRUITING
Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia	PHASE2	COMPLETED
Efavirenz for Patients With Alzheimer's Disease	PHASE1	COMPLETED
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer	PHASE1	COMPLETED
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease	PHASE1	COMPLETED
A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies	PHASE1	UNKNOWN
A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants	PHASE1	COMPLETED
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects	PHASE1	NOT_YET_RECRUITING
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease	PHASE1	COMPLETED
A Study to Evaluate the Effect of Genotype on LY2216684	PHASE1	COMPLETED
The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIH	PHASE1	UNKNOWN
Connecting Breath and Mind for CYP With Long COVID	nan	UNKNOWN
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients	nan	COMPLETED
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
Biomarkers of CYP2D6 and CYP3A4 Variability in Pediatrics	nan	COMPLETED
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia	nan	NOT_YET_RECRUITING
Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva	nan	COMPLETED
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis	nan	COMPLETED
Pharmacogenomic Profiling of Pediatric Patients	nan	COMPLETED
Clopidogrel Preventive Effect Based on CYP2C19 Genotype in Ischemic Stroke	nan	COMPLETED
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors	nan	COMPLETED
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics	nan	COMPLETED
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk	nan	COMPLETED
Influence of CYP2C19 Genotype on Safety and Efficacy of Voriconazole in Pediatric Patients With Hematologic Malignancy	nan	UNKNOWN
CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CYP2A13 binder may also engage these)

Protein	Name	Similarity
CYP2A7	Cytochrome P450 2A7 (EC 1.14.14.1) (CYPIIA7)	1.000	landscape →
Q05556	—	1.000	Q05556 →
Q05555	—	1.000	Q05555 →
CYP2A6	Cytochrome P450 2A6	1.000	landscape →
P10610	—	0.999	P10610 →
P20812	—	0.996	P20812 →
P33264	—	0.996	P33264 →
CYP2C19	Cytochrome P450 2C19	0.996	landscape →
P15392	—	0.996	P15392 →
P33263	—	0.995	P33263 →
O55071	—	0.995	O55071 →
P00180	—	0.994	P00180 →
P17666	—	0.994	P17666 →
P33272	—	0.994	P33272 →
Q08078	—	0.994	Q08078 →
Q64583	—	0.994	Q64583 →
P15123	—	0.993	P15123 →
CYP2C8	Cytochrome P450 2C8	0.993	landscape →
CYP2C18	Cytochrome P450 2C18	0.992	landscape →
P33265	—	0.992	P33265 →
E9Q5K4	—	0.992	E9Q5K4 →
CYP2B6	Cytochrome P450 2B6	0.991	landscape →
P20852	—	0.991	P20852 →
Q64458	—	0.991	Q64458 →
P33262	—	0.990	P33262 →
P24470	—	0.990	P24470 →
P33267	—	0.990	P33267 →
P05179	—	0.989	P05179 →
O18809	—	0.989	O18809 →
P11371	—	0.989	P11371 →